<DOC>
	<DOCNO>NCT00789581</DOCNO>
	<brief_summary>This randomize , Phase III , open-label , multicenter study .</brief_summary>
	<brief_title>A Randomized Trial Ixempra Versus Taxol Adjuvant Therapy Triple Negative Breast Cancer</brief_title>
	<detailed_description>Patients randomize 1:1 ratio receive one two different treatment arm . Patients treatment arm 1 receive AC follow ixabepilone . Patients treatment arm 2 receive AC follow weekly paclitaxel .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Female patient great equal to18 year age . 2 . Histologically confirm invasive unilateral breast cancer ( regardless histology ) . 3 . Earlystage breast cancer , define : Nodepositive disease : &gt; 0.2mm metastasis least one lymph node ( pN1mipN2b ) OR Nodenegative , primary tumor &gt; 1.0 cm ( T1cT3 ) . 4 . Definitive locoregional surgery must complete specified : Patients must undergo either breast conservation surgery ( i.e. , lumpectomy ) total mastectomy . Surgical margin resect section must histologically free invasive adenocarcinoma ductal carcinoma situ . Surgical margin involve lobular carcinoma situ ( LCIS ) consider positive margin ; therefore , patient eligible study without additional resection . Patients must complete axillary lymph node sample pathologic evaluation axillary lymph node specify : Sentinel node biopsy and/or either lymph node sample procedure axillary dissection . 5 . Multicentric multifocal invasive breast cancer eligible locoregional surgery complete describe . 6 . Patients synchronous bilateral cancer eligible : All cancer triplenegative phenotype , define ER , PR , HER2 . Eligibility base high stage grouping . 7 . HER2 negative tumor . HER2 negativity must confirm one following : FISHnegative ( FISH ratio &lt; 2.2 ) , IHC 01+ , IHC 23+ AND FISHnegative ( FISH ratio &lt; 2.2 ) . 8 . Estrogen receptor negative ( &lt; 10 % stain IHC estrogen receptor ) . 9 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 10 . Patient must &lt; = 84 day complete definitive primary breast surgery ( either lumpectomy mastectomy ) . 11 . MammoSite brachytherapy radiation acceptable perform immediately follow surgery prior chemotherapy . It recommend chemotherapy start earlier 2 week follow removal MammoSite balloon catheter . 12 . Adequate hematologic function , define : Absolute neutrophil count ( ANC ) &gt; 1500/mm3 Platelet count &gt; =100,000/mm3 Hemoglobin &gt; 9 g/dL 13 . Adequate liver function , define : AST ALT &lt; =2.5 x upper limit normal ( ULN ) Total bilirubin &lt; =1.5 x ULN ( unless patient grade 1 bilirubin elevation due Gilbert 's disease similar syndrome involve slow conjugation bilirubin ) . 14 . Adequate renal function , define : Serum creatinine &lt; =1.5 x ULN 15 . Complete stag workup &lt; =12 week prior initiation study treatment compute tomography ( CT ) scan chest abdomen/pelvis ( abdomen/pelvis prefer ; abdomen accept ) , either positron emission tomography ( PET ) scan bone scan . 16 . Adequate cardiac function , define leave ventricular ejection fraction ( LVEF ) value &gt; 50 % ( normal per institutional guideline ) MUGA scan echocardiogram ( ECHO ) . 17 . Adequate recovery recent surgery . At least 1 week must elapse time minor surgery ( i.e. , sentinel node biopsy , portacath ( placement ) ; least 3 week must elapse time major surgery ( i.e. , lumpectomy , partial total mastectomy , axillary lymph node dissection , breast reconstruction procedure ) . 18 . Patients previous history invasive cancer ( include breast cancer ) eligible definitive treatment complete 5 year prior initiate current study treatment , evidence recurrent disease . 19 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . 20 . Patient must accessible treatment followup . 21 . Women childbearing potential must agree use acceptable method birth control avoid pregnancy duration study treatment , 3 month thereafter . 22 . All patient must able understand investigational nature study give write informed consent prior study entry . 1 . Women pregnant breastfeeding . 2 . History previous diagnosis invasive breast cancer ( unless treat &gt; 5 year previously recurrence ) . History previously treat ductal carcinoma situ ( DCIS ) acceptable . 3 . Any evidence suspicion metastatic disease ipsilateral axillary lymph node . 4 . Any tumor &gt; =T4 ( cutaneous invasion , deep adherence , inflammatory breast cancer ) . 5 . Previous anthracycline chemotherapy . 6 . Concurrent use CYP3A4 inhibitor 72 hour prior initiation study treatment end treatment ixabepilone . 7 . Previous treatment breast cancer ( include neoadjuvant chemotherapy ) . 8 . Previous cancer ( exception nonmelanoma skin cancer cervical carcinoma situ ) past 5 year ( include invasive contralateral breast cancer ) . 9 . Peripheral neuropathy &gt; grade 1 per NCI CTCAE v3.0 . 10 . Cardiac disease , include : congestive heart failure ( CHF ) &gt; Class II per New York Heart Association ( NYHA ) classification ; unstable angina ( anginal symptom rest ) newonset angina ( i.e. , begin within last 3 month ) , myocardial infarction within past 6 month ; symptomatic CHF , unstable angina pectoris , cardiac arrhythmia , cardiac ventricular arrhythmia require antiarrhythmic therapy . 11 . History hypersensitivity CremophorEL ( polyoxyethylated castor oil ) drug formulate CremophorEL paclitaxel . 12 . Use investigational agent within 30 day administration first dose study drug . 13 . Patients may receive investigational anticancer treatment participate study . 14 . Concurrent severe , uncontrolled infection intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 15 . Mental condition would prevent patient comprehension nature , risk associate , study . 16 . Inability comply study and/or followup procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Ixabepilone</keyword>
	<keyword>TITAN</keyword>
</DOC>